Air T ( ($AIRT) ) has shared an update. Air T, Inc. has updated its investor presentation, reflecting its financial performance and strategic ...

RICHMOND, Calif.-- (BUSINESS WIRE)-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and first quarter 2025 financial results.

She holds an MBA from Harvard Business School and a BS in Biomedical Engineering from the University of Wisconsin-Madison. First Quarter 2025 Financial Highlights ...

Delivered an oral presentation at ASCO 2025 Annual Meeting, demonstrating extended median progression-free survival (mPFS) in ...

Physician engagement and enthusiasm for anito-cel continues to build following these data presentations and as more sites gain experience with anito-cel through iMMagine-3, our earlier-line study.

First Quarter 2025 Financial Highlights Cash Position: Cash and cash equivalents, and short-term investments of $136.5 million as of March 31, 2025, compared with $147.3 million as of December 31 ...

NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines ...

Key presentations highlight the Phase 3 trials of AXS-12 for narcolepsy, detailing its effects on symptom severity and functional impairment, while also addressing real-world applications of ...

The full presentation can be found here. Fruquintinib is a selective oral inhibitor of vascular endothelial growth factor receptors (“VEGFR”) -1, -2 and -3, which play a pivotal role in ...

Element 25 Limited ( ($AU:E25) ) just unveiled an update. Element 25 Limited presented at the 2025 Diggers & Dealers Mining Forum, highlighting ...

Upcoming oral presentation: "INB-200: Phase 1 Study of Gene-Modified Autologous Gamma-Delta (γδ) T Cells in Newly Diagnosed Glioblastoma Multiforme (GBM) Patients Receiving Maintenance ...